review Open AccessTop 1% cited

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Blood · 2016 · Vol. 129(4) · pp. 424–447

Hartmut Döhner✉(Universität Ulm)Elihu H. Estey(Fred Hutch Cancer Center)David Grimwade(King's College London)Sergio Amadori(University of Rome Tor Vergata)Frederick R. Appelbaum(Fred Hutch Cancer Center)Thomas Büchner(University of Münster)Hervé Dombret(Assistance Publique – Hôpitaux de Paris)Benjamin L. Ebert(Brigham and Women's Hospital)Pierre Fenaux(Hôpital Saint-Louis)Richard A. Larson(University of Chicago)Ross L. Levine(Memorial Sloan Kettering Cancer Center)Francesco Lo‐Coco(University of Rome Tor Vergata)Tomoki Naoe(National Hospital Organization)Dietger Niederwieser(Leipzig University)Gert J. Ossenkoppele(Vrije Universiteit Amsterdam)Miguel Á. Sanz(Hospital Universitari i Politècnic La Fe)Jorge Sierra(Josep Carreras Leukaemia Research Institute)Martin S. Tallman(Memorial Sloan Kettering Cancer Center)Hwei‐Fang Tien(National Taiwan University Hospital)Andrew H. Wei(Monash University)Bob Löwenberg(Erasmus MC)Clara D. Bloomfield(The Ohio State University)

View via DOI Full-text PDF

Abstract

The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.

Acute Myeloid Leukemia Research Histone Deacetylase Inhibitors Research Chronic Myeloid Leukemia TreatmentsMedicineExpert opinionMinimal residual diseaseGenetic testingDiseaseMyeloid leukemiaIntensive care medicineOncologyFamily medicineLeukemia

MeSH terms

Drug Administration ScheduleAdultAntineoplastic AgentsGenetic TestingHumansInternational CooperationRisk FactorsTransplantation, AutologousLeukemia, Myeloid, AcuteImmunophenotypingTreatment OutcomePractice Guidelines as TopicNeoplasm, ResidualHematopoietic Stem Cell TransplantationDisease Management